All In Biotech

NDA 210428 · Spil

Kapspargo Sprinkle

Metoprolol Succinate · Oral

Last checked: Nov 19, 2026Latest source record: Apr 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jan 26, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

302

56 Phase 3, 19 recruiting

FAERS reports

64,013

40,110 serious, 5,990 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 12, 2023.

KAPSPARGO Sprinkle is a beta 1 -adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Angina Pectoris. (1.2) • Heart Failure, to reduce the risk of cardiovascular mortality and heart-failure hospitalizations in patients with heart failure. (1.3) 1.1 Hypertension KAPSPARGO Sprinkle is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular...

Mechanism: Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • KAPSPARGO SPRINKLE · METOPROLOL SUCCINATE EQ 100MG TARTRATE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • KAPSPARGO SPRINKLE · METOPROLOL SUCCINATE EQ 25MG TARTRATE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • KAPSPARGO SPRINKLE · METOPROLOL SUCCINATE EQ 200MG TARTRATE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • KAPSPARGO SPRINKLE · METOPROLOL SUCCINATE EQ 50MG TARTRATE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Metoprolol" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue4,958
  • diarrhoea4,077
  • dyspnoea3,874
  • nausea3,812
  • dizziness3,238
  • drug ineffective3,140
  • off label use3,106
  • headache2,969
  • death2,656
  • asthenia2,454
  • pain2,317
  • fall2,218

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004586
2005535
2006678
20071,507
2008857
20091,212
2010935
20111,611
20121,916
2013567
20141,012
20151,828
20162,529
20173,265
20184,179
20194,262
20204,217
20213,973
20224,653
20235,082
20246,106
20257,085
20265,418

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kapspargo Sprinkle (Metoprolol Succinate)

2024 spending

$2.6M

Beneficiaries

14,577

44,309 claims

Per beneficiary

$182

$2.02 per unit

View as table
YearSpending
2020$1,307,312
2021$1,623,592
2022$2,023,722
2023$2,223,865
2024$2,647,360

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,994 on PubMed

Sponsor: Spil

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.